Tech giants tout AI-enabled drug discovery
AXIOS
Adriel Bettelheim
October 28, 2026
Nvidia and Anthropic yesterday provided new signs of how AI models are accelerating drug development.
Why it matters: Aspects of drug research are shifting from traditional labs to AI platforms, helping diversify tech companies' revenue streams and reshape public sentiment.
Driving the news: Nvidia and a research consortium focused on dementia announced a new effort to use AI tools to sift through unpublished or proprietary Alzheimer's research data to find treatments faster.
Researchers say inaccessible data is slowing progress with more than 10 million new dementia cases diagnosed each year.
The C-BRAIN consortium wants to use Nvidia's software and engineering expertise to learn how Alzheimer's develops and progresses, directly from human brain data.
To get there, it envisions training AI with data that's been buried in unpublished findings, unsuccessful experiments and proprietary datasets from member institutions.
Anthropic, meanwhile, said it acquired a lab developing a drug for childhood forms of muscular dystrophy and could have human trials up as soon as 2028.
Its founder used Anthropic's Claude AI model to organize contracts, logistics and experiments with 11 external labs, and delegated other aspects of the venture's operations to Claude.
Anthropic more broadly envisions AI proposing initial designs for new treatments and drafting regulatory filings and running clinical trials later in the development process.